Market Cap 262.24M
Revenue (ttm) 7.15M
Net Income (ttm) -20.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -288.11%
Debt to Equity Ratio 0.00
Volume 178,100
Avg Vol 480,214
Day's Range N/A - N/A
Shares Out 57.01M
Stochastic %K 24%
Beta 0.81
Analysts Strong Sell
Price Target $7.50

Company Profile

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Industry: Biotechnology
Sector: Healthcare
Phone: 551 321 2234
Address:
2 Headquarters Plaza, East Building 11th Floor, Morristown, United States
X23mulder
X23mulder Aug. 25 at 3:28 PM
$WHWK **WHWK monthly chart:** a potential **rounded-bottom reversal** is developing. The structure looks bullish, but confirmation still requires a **monthly breakout above ~$5.50** (52-week high). ([MarketWatch][1]) **Above $5.50:** breakout confirmation → **$6.30–$7.00** becomes the next technical zone. **Bottom line:** *WHWK is approaching the neckline of a long-term rounded bottom. A decisive monthly close above $5.50 could trigger the next leg higher.*
0 · Reply
X23mulder
X23mulder Aug. 25 at 1:34 PM
$WHWK 🧨🧨. GREAT Slowly
0 · Reply
X23mulder
X23mulder Aug. 24 at 5:12 PM
$WHWK 👁️👃👁️ Take an eye http://es.investing.com/equities/aerpio-pharma?utm_source=investing_app&utm_medium=share_link&utm_campaign=share_instrument
0 · Reply
X23mulder
X23mulder Aug. 24 at 3:38 PM
$WHWK 🧨 THE BULL Case with 14$ Target 1️⃣. Strong cash position: ~$190M in cash, providing a solid downside cushion and runway into 2H 2028. 2️⃣. Multiple clinical catalysts: Three ADC programs in the clinic, with initial data expected in 1H 2027. 3️⃣. Low valuation: At ~$4.73, the market values WHWK at only ~$270M; $14 would imply ~$800M, still reasonable if the pipeline delivers positive data. THE
0 · Reply
X23mulder
X23mulder Aug. 24 at 3:31 PM
$WHWK BULLISH GREAT WEEKLY & MONTHLY CHART One-line bull case: “At $14, WHWK would still be valued below $1B, which could be justified if its well-funded ADC pipeline generates positive Phase 1 data and demonstrates meaningful clinical differentiation.”
0 · Reply
PatrickandFrankie
PatrickandFrankie Aug. 6 at 8:06 PM
$WHWK well that was a timely buy for a change 😂! Nobody following?
0 · Reply
PatrickandFrankie
PatrickandFrankie Aug. 3 at 7:16 PM
$WHWK buying it at pipe financing price with Avoro capital owning almost 20pct of the company !
0 · Reply
MikiTrader
MikiTrader Jul. 19 at 12:19 PM
$WHWK Get it together and try again. Prove the company's technical capabilities by highlighting that it is the only biparatopic ADC targeting SCLC and neuroendocrine tumors, and that its entry into clinical trials is the ultimate proof.
0 · Reply
deedeethegenius
deedeethegenius Jul. 2 at 2:00 PM
$CULP is a $40M market cap company that just collected a $7M tariff refund — that’s ~18% of the ENTIRE market cap in cash, banked in Q1. Net debt drops to ~$5M. Add the operating turn: Q4 sales +6%, bedding +12.5% YoY, adj EBITDA up 74% QoQ, restructuring complete with $20M+ annualized savings, guiding breakeven-to-positive EBITDA next quarter. At 0.2x sales, the refund alone is a repricing event. 🔥 Today’s gainers by size: $NEXA ($1.9B) $COLL ($1.2B) $CTNM ($610M) $WHWK ($230M) Risk appetite is running down the cap stack. 📈
0 · Reply
MikiTrader
MikiTrader Jun. 7 at 9:14 PM
$WHWK Maybe it's worth taking a break and coming back with a fresh perspective.
0 · Reply
Latest News on WHWK
Whitehawk Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 10:00 AM EDT - 4 weeks ago

Whitehawk Therapeutics Earnings release: Q2 2026


Whitehawk Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 10:00 AM EDT - 4 weeks ago

Whitehawk Therapeutics Quarterly report: Q2 2026


Whitehawk Therapeutics Slides: Corporate presentation

Aug 5, 2026, 9:00 AM EDT - 4 weeks ago

Whitehawk Therapeutics Slides: Corporate presentation


Whitehawk Therapeutics initiated with a Buy at B. Riley

2026-06-25T12:45:47.000Z - 2 months ago

Whitehawk Therapeutics initiated with a Buy at B. Riley


Whitehawk Therapeutics Transcript: AGM 2026

Jun 11, 2026, 1:00 PM EDT - 2 months ago

Whitehawk Therapeutics Transcript: AGM 2026


Whitehawk Therapeutics presents real-world analysis on SEZ6

2026-05-31T21:35:57.000Z - 3 months ago

Whitehawk Therapeutics presents real-world analysis on SEZ6


Whitehawk Therapeutics announces $87.5M private placement

2026-05-13T16:50:24.000Z - 3 months ago

Whitehawk Therapeutics announces $87.5M private placement


Whitehawk Therapeutics reports Q1 EPS (32c), consensus (33c)

2026-05-07T13:20:45.000Z - 4 months ago

Whitehawk Therapeutics reports Q1 EPS (32c), consensus (33c)


Whitehawk Therapeutics Earnings release: Q1 2026

May 7, 2026, 9:00 AM EDT - 4 months ago

Whitehawk Therapeutics Earnings release: Q1 2026


Whitehawk Therapeutics Quarterly report: Q1 2026

May 7, 2026, 9:00 AM EDT - 4 months ago

Whitehawk Therapeutics Quarterly report: Q1 2026


Whitehawk Therapeutics Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Whitehawk Therapeutics Slides: Corporate presentation


Whitehawk Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Whitehawk Therapeutics Proxy statement: Proxy filing


Whitehawk Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Whitehawk Therapeutics Proxy statement: Proxy filing


Whitehawk Therapeutics management to meet with Oppenheimer

2026-04-16T19:41:37.000Z - 4 months ago

Whitehawk Therapeutics management to meet with Oppenheimer


Whitehawk Therapeutics initiated with an Outperform at Citizens

2026-04-16T09:25:48.000Z - 4 months ago

Whitehawk Therapeutics initiated with an Outperform at Citizens


Whitehawk Therapeutics presents analysis of MUC16 at SGO

2026-04-10T11:13:42.000Z - 5 months ago

Whitehawk Therapeutics presents analysis of MUC16 at SGO


Whitehawk Therapeutics reports Q4 EPS (34c) vs. (67c) last year

2026-03-12T12:07:42.000Z - 5 months ago

Whitehawk Therapeutics reports Q4 EPS (34c) vs. (67c) last year


Whitehawk Therapeutics Annual report: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Whitehawk Therapeutics Annual report: Q4 2025


Whitehawk Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 8:00 AM EDT - 5 months ago

Whitehawk Therapeutics Earnings release: Q4 2025


Whitehawk Therapeutics initiated with a Buy at JonesResearch

2025-12-22T17:05:25.000Z - 8 months ago

Whitehawk Therapeutics initiated with a Buy at JonesResearch


Whitehawk Therapeutics appoints Dugan as Chief Medical Officer

2025-12-01T13:15:59.000Z - 9 months ago

Whitehawk Therapeutics appoints Dugan as Chief Medical Officer


Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year

2025-11-06T13:11:09.000Z - 10 months ago

Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year


Whitehawk Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Whitehawk Therapeutics Quarterly report: Q3 2025


Whitehawk Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Whitehawk Therapeutics Earnings release: Q3 2025


Whitehawk Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Whitehawk Therapeutics Quarterly report: Q2 2025


Whitehawk Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 1 year ago

Whitehawk Therapeutics Earnings release: Q2 2025


Whitehawk Therapeutics Slides: Corporate Presentation

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Whitehawk Therapeutics Slides: Corporate Presentation


Whitehawk Therapeutics Transcript: Fireside Chat

Jun 26, 2025, 10:00 AM EDT - 1 year ago

Whitehawk Therapeutics Transcript: Fireside Chat


Whitehawk Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Whitehawk Therapeutics Quarterly report: Q1 2025


Whitehawk Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Whitehawk Therapeutics Earnings release: Q1 2025


Whitehawk Therapeutics Slides: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Whitehawk Therapeutics Slides: Q1 2025


Whitehawk Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Whitehawk Therapeutics Proxy statement: Proxy Filing


Whitehawk Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Whitehawk Therapeutics Proxy statement: Proxy Filing


Whitehawk Therapeutics Earnings Call Transcript: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Whitehawk Therapeutics Earnings Call Transcript: Q4 2024


Whitehawk Therapeutics Annual report: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Whitehawk Therapeutics Annual report: Q4 2024


Whitehawk Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Whitehawk Therapeutics Earnings release: Q4 2024


X23mulder
X23mulder Aug. 25 at 3:28 PM
$WHWK **WHWK monthly chart:** a potential **rounded-bottom reversal** is developing. The structure looks bullish, but confirmation still requires a **monthly breakout above ~$5.50** (52-week high). ([MarketWatch][1]) **Above $5.50:** breakout confirmation → **$6.30–$7.00** becomes the next technical zone. **Bottom line:** *WHWK is approaching the neckline of a long-term rounded bottom. A decisive monthly close above $5.50 could trigger the next leg higher.*
0 · Reply
X23mulder
X23mulder Aug. 25 at 1:34 PM
$WHWK 🧨🧨. GREAT Slowly
0 · Reply
X23mulder
X23mulder Aug. 24 at 5:12 PM
$WHWK 👁️👃👁️ Take an eye http://es.investing.com/equities/aerpio-pharma?utm_source=investing_app&utm_medium=share_link&utm_campaign=share_instrument
0 · Reply
X23mulder
X23mulder Aug. 24 at 3:38 PM
$WHWK 🧨 THE BULL Case with 14$ Target 1️⃣. Strong cash position: ~$190M in cash, providing a solid downside cushion and runway into 2H 2028. 2️⃣. Multiple clinical catalysts: Three ADC programs in the clinic, with initial data expected in 1H 2027. 3️⃣. Low valuation: At ~$4.73, the market values WHWK at only ~$270M; $14 would imply ~$800M, still reasonable if the pipeline delivers positive data. THE
0 · Reply
X23mulder
X23mulder Aug. 24 at 3:31 PM
$WHWK BULLISH GREAT WEEKLY & MONTHLY CHART One-line bull case: “At $14, WHWK would still be valued below $1B, which could be justified if its well-funded ADC pipeline generates positive Phase 1 data and demonstrates meaningful clinical differentiation.”
0 · Reply
PatrickandFrankie
PatrickandFrankie Aug. 6 at 8:06 PM
$WHWK well that was a timely buy for a change 😂! Nobody following?
0 · Reply
PatrickandFrankie
PatrickandFrankie Aug. 3 at 7:16 PM
$WHWK buying it at pipe financing price with Avoro capital owning almost 20pct of the company !
0 · Reply
MikiTrader
MikiTrader Jul. 19 at 12:19 PM
$WHWK Get it together and try again. Prove the company's technical capabilities by highlighting that it is the only biparatopic ADC targeting SCLC and neuroendocrine tumors, and that its entry into clinical trials is the ultimate proof.
0 · Reply
deedeethegenius
deedeethegenius Jul. 2 at 2:00 PM
$CULP is a $40M market cap company that just collected a $7M tariff refund — that’s ~18% of the ENTIRE market cap in cash, banked in Q1. Net debt drops to ~$5M. Add the operating turn: Q4 sales +6%, bedding +12.5% YoY, adj EBITDA up 74% QoQ, restructuring complete with $20M+ annualized savings, guiding breakeven-to-positive EBITDA next quarter. At 0.2x sales, the refund alone is a repricing event. 🔥 Today’s gainers by size: $NEXA ($1.9B) $COLL ($1.2B) $CTNM ($610M) $WHWK ($230M) Risk appetite is running down the cap stack. 📈
0 · Reply
MikiTrader
MikiTrader Jun. 7 at 9:14 PM
$WHWK Maybe it's worth taking a break and coming back with a fresh perspective.
0 · Reply
HectorNumba9
HectorNumba9 Jun. 3 at 4:25 PM
$WHWK This i was right. This u have plenty of time to rack up. Gonna go up like a slow train/savings account. Big players are here till least 2028-2029. Remember stocks there's always that chance to get screwed
0 · Reply
AlertsAndNews
AlertsAndNews May. 31 at 10:37 PM
$WHWK Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
0 · Reply
smartmoney43
smartmoney43 May. 26 at 3:55 PM
$WHWK 😍😍
0 · Reply